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BACKGROUND: The United Kingdom has poorer cancer outcomes than many other countries due partly to delays in diagnosing
symptomatic cancer, leading to more advanced stage at diagnosis. Delays can occur at the level of patients, primary care, systems and
secondary care. There is considerable potential for interventions to minimise delays and lead to earlier-stage diagnosis.
METHODS: Scoping review of the published studies, with a focus on methodological issues.
RESULTS: Trial data in this area are lacking and observational studies often show no association or negative ones. This review offers
methodological explanations for these counter-intuitive findings.
CONCLUSION: While diagnostic delays do matter, their importance is uncertain and must be determined through more sophisticated
methods.
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It is now well established that the United Kingdom has poorer
cancer outcomes compared with much of Western Europe (Berrino
et al, 2007). The consensus is that one of the major reasons for this is
more advanced stage at diagnosis. One solution to this problem is to
reduce diagnostic delays on the premise that this will lead to earlier
stage diagnosis and improved outcomes. This paper will contextua-
lise the diagnostic process and critically appraise the evidence that
examines the association between delays and cancer outcomes.
Tumours typically grow progressively, with the ‘doubling time’
(a recognised period of time that it takes for the tumour to double
in size) being a key measure of speed of tumour growth. This varies
between types of tumour but even within tumour types, there can
be significant variation, leading to unpredictable differences in
patterns of symptoms and symptom complexes, speed of onset and
progression of symptoms (Ford and Mitchell, 1999).
Around 90% of cancers will present symptomatically (Hamilton,
2008). There is a prevailing hypothesis within primary care that
most patients have symptoms that are either self-limiting or
represent chronic and benign disease until proven otherwise. In
cancer this may be counter-productive, and creates a dilemma for
primary care. On one hand, health professionals, whether they are
general practitioners (GPs) or practice nurses (who do much
chronic disease management and monitoring), have to be vigilant
for ‘alarm symptoms’ (Jones et al, 2007) that are rarely caused by
cancer. On the other hand, they are aware that most potential
cancer symptoms are almost exactly the same as those of common
chronic or minor diseases. Furthermore, there may be difficulty in
assessing the positive predictive value of symptoms and what they
really mean, and placing these within the current National Institute
for Health and Clinical Excellence (NICE) urgent suspected referral
guidelines (NICE, 2005). These have been shown to have a low
predictive value in determining cancer (Allgar et al, 2006) and may
prioritise patients who stand to gain least from urgent referral in
terms of survival (Neal et al, 2007).
Hence, the vexed question of what can be done to reduce delays
is of paramount importance. The need to determine the exact
relationship between symptom duration and clinical outcomes
(usually survival, but sometimes stage as a proxy for survival) is
essential. Delays may occur at any stage of the diagnostic cancer
journey. There may be ‘patient delays’ where the patient may not
recognise suspicious cancer symptoms or act on them. There may
also be ‘primary care delays’, where there are unnecessary delays in
the recognition, onward referral of or investigation for suspicious
symptoms. After this, there may be ‘system delays’ where there may
be a considerable wait for either non-urgent referrals (as is the case
for the majority of cancer patients) or GP-initiated diagnostic
investigations. Finally, ‘secondary care delays’ are where there may be
prolonged time spent in secondary care before diagnosis, sometimes
due to patients being investigated in the ‘wrong’ specialty.
While a small element of delay is inherently inevitable in all cancer
diagnostic pathways, it is likely that in a significant percentage of
patients there is considerable preventable delay. The important
question is how much of this preventable delay leads to poorer
outcomes. If people could be diagnosed earlier, what difference
would this make to survival and other clinical outcomes?
SCOPING REVIEW OF THE LITERATURE
The existing literature in this area is very mixed and, at times,
confusing. There is a dearth of trial evidence (e.g. of interventions
to reduce delays). Indeed, recent systematic reviews examining
factors associated with delay in colorectal and upper gastrointest-
inal cancers identified no trials at all (Macdonald et al, 2006;
Mitchell et al, 2008). Most of the published literature reports data,
inevitably, from observational studies. It may seem logical that
outcomes should worsen with longer symptom duration, but there
are a number of observational studies that seem to show the
opposite, across a wide range of cancers. How and why should this
be so? A major systematic review of the world literature on this
topic is due to report in early 2010. As a prelude to this, a scoping *Correspondence: Dr RD Neal; E-mail: nealrd@cf.ac.uk
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some studies reported findings for more than one cancer in a single
paper (Table 1). These included two systematic reviews: one
well-conducted review for breast cancer that showed a clear
association between shorter symptom durations and better
outcomes (Richards et al, 1999); and one less rigorous review for
lung cancer that showed a weakly positive association (Jensen et al,
2001). Of the 45 other studies, 9 showed a positive association, 9
showed a negative association (i.e. shorter symptom durations were
associated with worse outcomes) and 29 showed no association.
A close examination of this body of literature has identified
multiple methodological issues that need to be taken into considera-
tion when trying to determine the association between symptom
duration and clinical outcomes. These will be discussed in turn.
Different definitions of delays
Different studies have used different definitions of delay, making
comparison between studies and settings very difficult. Some of
this is inevitable, given the different structures of international
health services, including the varying roles of primary care, and
the access of patients directly to secondary care specialists and
diagnostic investigations. However, there seems to be some broad
consensus that ‘patient delay’ may occur in the time period from
first experience of a potential cancer symptom to telling a health
professional about it. Similarly, there is broad consensus that
‘primary care delay’ can occur in the time period from first
presentation of the symptom to onward specialist referral to GP-
initiated diagnostic investigation. ‘System delay’ would occur in
the time that it then takes for these investigations to happen, and
delays in ‘secondary care’ happen during the time from first being
seen in secondary care to diagnosis. Some papers also report
‘treatment delay’ – the time from diagnosis to first treatment.
Different ways of measuring delays
There are many ways of measuring delays and each has its own
problems. Questions can be asked of the patient, the health
professional or the medical record(s). Patient-centred studies are
most likely to represent truer ‘patient delays’, but the answers that
patients give vary enormously depending on how the questions are
asked. In recent years, in-depth qualitative studies have shown that
patients report symptoms attributable to their cancer for much
longer than previously thought, as in, for example, lung (Corner
et al, 2005) and ovarian cancers (Bankhead et al, 2005). Surveys
with closed-response questions generally report much shorter
delays, as is the case for data from the NHS cancer survey (Allgar
and Neal, 2005). Additionally, any interview or patient-completed
survey is prone to recall bias, which is hard to avoid.
Studies that use medical records to examine diagnostic delays
have advantages in that records are made contemporaneously, and
are not prone to recall bias. However, they are prone to missing
data, which is often non-random. For example, primary care
records are more likely to contain an entry for abdominal
pain if the clinician thinks that the pain is significant. If they do
not, the pain may not have been recorded even though it was
presented. Studies using records are good at capturing events such
as referrals and investigations, but doing so precisely for diagnosis
can be difficult. When exactly is a diagnosis made: when a
pathological specimen is reported, when the multi-disciplinary
team meets, when patients are told or when a diagnosis
confirmation letter is coded in primary care? This can cause
difficulty and errors but there are algorithms for standardising this
(Tate et al, 2009).
The significance of these difficulties is that the context for how
delay is counted and captured needs to be understood. Until then,
comparisons between studies may be impossible or give very
conflicting results.
Difficulties in comparing cancers that behave very
differently
It is difficult to make between-cancer comparisons given the
variation in how they present and grow. What may hold for breast
cancer may have no bearing on colorectal, lung or prostate cancer.
Table 1 Summary of findings of scoping review
Cancer site Evidence (‘positive’¼longer delay associated with poorer outcomes, ‘negative’¼longer delay associated with better outcomes)
Breast Systematic review: 1 positive study within this scoping review (Richards et al, 1999)
Subsequent studies: 1 positive (Arndt et al, 2002), 1 negative (Sainsbury et al, 1999)
Lung Systematic review: 1 weakly positive study within this scoping review (Jensen et al, 2001)
5 subsequent studies: 3 negative (Yoshimoto et al, 2002; Myrdal et al, 2004; Neal et al, 2007)
2 no association (Koyi et al, 2002; Quarterman et al, 2003)
Colorectal 10 no association (Robinson et al, 1984; Stubbs and Long, 1986; Kyle et al, 1991; Majumdar et al, 1999; Roncoroni et al, 1999; Young et al, 2000; Kiran
and Glass, 2002; Gonzalez-Hermoso et al, 2004; Bharucha et al, 2005; Neal et al, 2007)
4 negative (Mulcahy and O’Donoghue, 1997; Langenbach et al, 2003; Olsson et al, 2004; Rupassara et al, 2006), however, for three of these, the
association disappears if data are corrected for emergency admissions (Mulcahy and O’Donoghue, 1997; Olsson et al, 2004; Rupassara et al, 2006)
Melanoma 5 no association (Krige et al, 1991; Blum et al, 1999; Oliviera et al, 1999; Brochez et al, 2001; Baade et al, 2006)
1 weakly positive (Betti et al, 2003)
Upper
gastrointestinal
1 no association (oesophageal; Kotz et al, 2006) and 2 no association (gastric; Martin et al, 1997; Porta et al, 1991)
1 positive (oesophageal; Martin et al, 1997) and 1 weakly positive (oesophageal; Porta et al, 1991)
Ovarian 3 no association (Robinson et al, 1984; Kirwan et al, 2002; Neal et al, 2007)
1 positive (Wikborn et al, 1996)
Endometrial 1 negative (Crawford et al, 2002)
1 no association (Menczer et al, 1995)
Testicular 1 positive (Hernes et al, 1996)
1 no association (Toklu et al, 1999)
Bladder 2 no association (Robinson et al, 1984; Liedberg et al, 2003)
Prostate 1 no association (Neal et al, 2007)
Oropharyngeal 1 positive (Pitchers and Martin, 2006)
Laryngeal 1 positive (Teppo et al, 2003)
Retinoblastoma 1 no association (Goddard et al, 1999)
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pathway are likely to be very different between different cancers
and what works for one may well not work for another. However,
there are some findings that may have relevance for different
cancers.
Difficulties in measuring outcomes
Survival is the most important outcome. While it is the primary
outcome in some parts of the literature, others use different
measures as a proxy for survival. These include stage (which
correlates well with survival), and different treatment options
(such as eligibility for potentially curative treatments). Health-
related quality of life measures are also of importance. The
published literature reports a variety of outcome measures, and
this can make comparison between studies difficult.
Failure to account for speed of growth of tumours
Tumours of a single cancer type can appear to be similar but grow
at very different rates and with different levels of aggressiveness. A
fast-growing tumour is likely to cause symptoms with more rapid
progression, leading to a quicker diagnostic journey but worse
outcomes because of aggressive growth and spread. Conversely, a
slower-growing tumour is likely to cause symptoms that develop
more insidiously and take longer to diagnose. However, the
outcome may be better, given that curative life-prolonging
treatments may be offered. Hence, there is what is sometimes
called a ‘paradox’ (although it is really nothing of the sort) where
patients with shorter delays may do worse than those with longer
ones. This phenomenon has been described in several cancers, for
example, endometrial (Crawford et al, 2002) and colorectal
(Rupassara et al, 2006), but is likely to exist in more. It also
probably explains why the negative associations reported in some
colorectal cancer studies disappear when the data are corrected for
emergency admissions (Stapley et al, 2006).
The issue for the body of literature looking at the association
between delay and outcome is that many studies have not allowed
for differences in the speed of tumour growth in their analysis.
Many have simply analysed data for all patients together. It seems
hardly surprising therefore that many studies have shown
equivocal or negative findings.
Confounding effect of lead-time bias
Lead-time bias is the bias that may occur when outcomes are
compared, but where the onset of measuring ‘delay’ is different as
a result of diagnosis earlier in the natural history of the cancer, but
that will have no effect on the outcome. The Richards et al (1999)
systematic review of breast cancer reported that only 4 out of 87
included studies took lead-time bias into account.
CONCLUSION
In conclusion, diagnostic delays in cancer do matter, but it is hard
to quantify their impact on survival or mortality. The ‘amount’ that
they matter is clear in breast cancer but far less so in other cancer
types. More empirical work is needed to determine the importance
of delays and, in particular, the likely effect of interventions to
reduce delay in specific parts of the diagnostic journey. More work
is also needed to determine the effect of delays between diagnosis
and first treatment.
There are significant windows of opportunity to reduce
symptom duration through:
  Reducing patient delay by increasing awareness of symptoms
and the understanding of how and when to act on these.
  Reducing primary care delay by increasing awareness of
potential cancer symptoms among primary care clinicians, by
changing culture towards one where potential cancer symptoms
are considered suspicious until proven otherwise, and by
lowering the thresholds for referral or requesting GP-initiated
investigations.
  Reducing system delay, by revising and implementing new
urgent cancer referral guidance. These must account for the
considerable body of primary care-based research on the
meaning of symptoms and symptom complexes that has been
published since the last update (NICE, 2005). More importantly,
faster-track pathways are needed for diagnostic investigations
and for patients with potential cancer symptoms that do not
fulfil the urgent referral criteria. There is also a need for
innovations to reduce unnecessary delay, such as proceeding
straight to computerised tomography scan for a suspicious chest
X-ray, rather than referring back to the GP or directly to the
chest clinic.
Working to reduce delays in cancer diagnosis in these ways will
contribute to the ultimate goal of achieving earlier stage diagnosis
with its associated options for curative or life-prolonging
treatment.
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